Indoleamine 2,3-dioxygenase is a critical resistance mechanism in anti-tumor T cell immunotherapy targeting CTLA-4

Documenti analoghi

• Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
  di: Holmgaard, Rikke B., et al.
  Pubblicazione: (2013)
• Expression of indoleamine 2.3-dioxygenase by tumors induces local and systemic immunosuppressive effects in a murine melanoma model
  di: Holmgaard, Rikke B, et al.
  Pubblicazione: (2014)
• Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors
  di: Holmgaard, Rikke B., et al.
  Pubblicazione: (2016)
• Potentiation of immunomodulatory antibodies with oncolytic viruses for therapy of poorly-immunogenic tumors
  di: Zamarin, Dmitriy, et al.
  Pubblicazione: (2014)
• Indoleamine 2,3-dioxygenase and tumor-induced tolerance
  di: Munn, David H., et al.
  Pubblicazione: (2007)